PROBE-PD
  • Sobre
  • Projeto
  • Equipe
  • Publicações
  • Parkinson
  • Contato
  • Português
    • Português
  • Home
Escolha uma Página
Genetic risk of ADHD may boost odds of Alzheimer’s in old age

Genetic risk of ADHD may boost odds of Alzheimer’s in old age

por Fernando Rigon | dez 8, 2022 | News

Having a genetic predisposition to attention-deficit/hyperactivity disorder, or ADHD, is associated with cognitive decline and may predict Alzheimer’s disease in old age, early research released Thursday suggests. Recent large studies have hinted at a link...
Transcranial Direct Current Stimulation vs Sham for the Treatment of Inattention in Adults

Transcranial Direct Current Stimulation vs Sham for the Treatment of Inattention in Adults

por Fernando Rigon | out 12, 2022 | News

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that affects 2.5% of adults worldwide. Pharmacotherapy is the recommended initial treatment for most adults, but patient adherence can be low due to adverse effects and other concerns....
Molecular Psychiatry: Astrocyte Biomarker Signatures of Amyloid-β and Tau Pathologies in Alzheimer’s Disease

Molecular Psychiatry: Astrocyte Biomarker Signatures of Amyloid-β and Tau Pathologies in Alzheimer’s Disease

por Fernando Rigon | set 29, 2022 | News

In Alzheimer’s disease, reactive astrocytes can play an important role in the pathophysiology of the disease. Amyloid-β and tau tangles—the two main pathological hallmarks of Alzheimer’s disease—are associated with astrocyte reactivity. However, knowledge about...
Pitt Psychiatry Awarded $33.5M NIH Program Project Grant Focused on the Pathological and Clinical Progression of AD

Pitt Psychiatry Awarded $33.5M NIH Program Project Grant Focused on the Pathological and Clinical Progression of AD

por Fernando Rigon | set 14, 2022 | News

The National Institute on Aging (NIA) has awarded the University of Pittsburgh Department of Psychiatry a Program Project Grant (PPG) renewal for “The role of astrogliosis in aging and the pathological and clinical progression of Alzheimer’s disease.” The...
Study Challenges Dogma Behind Alzheimer’s Disease Drug Trials

Study Challenges Dogma Behind Alzheimer’s Disease Drug Trials

por Fernando Rigon | jul 19, 2022 | News

PITTSBURGH – Contrary to early studies, brain levels of enzymes that regulate DNA-folding drop as Alzheimer’s disease progresses, neuroscientists from the University of Pittsburgh, McGill University and Harvard University reported...
Página 1 de 3123»

Recent Posts

  • Genetic risk of ADHD may boost odds of Alzheimer’s in old age
  • Transcranial Direct Current Stimulation vs Sham for the Treatment of Inattention in Adults
  • Molecular Psychiatry: Astrocyte Biomarker Signatures of Amyloid-β and Tau Pathologies in Alzheimer’s Disease
  • Pitt Psychiatry Awarded $33.5M NIH Program Project Grant Focused on the Pathological and Clinical Progression of AD
  • Study Challenges Dogma Behind Alzheimer’s Disease Drug Trials

Website by